H.C. Wainwright Reiterates Neutral Rating on aTyr Pharma (ATYR): "viewing the upcoming 1Q26 Type C meeting with the FDA as a critical catalyst"
Tweet Send to a Friend
H.C. Wainwright analyst Joseph Pantginis reiterated a Neutral rating and {REMOVEPT} price target on aTyr Pharma (NASDAQ: ATYR)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
